HER2+ Breast Cancer KOL Interview – US, West Coast

HER2+ Breast Cancer KOL Interview – US, West Coast

  • March 2020 •
  • 18 pages •
  • Report ID: 5878945 •
  • Format: PDF
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.